United States — National Institutes of Health & China

United States — National Institutes of Health: The United States — National Institutes of Health supported a 2018 animal study that demonstrated the efficacy of the BDBV289-N antibody candidate against the Bundibugyo strain.

China: China>>> is developing an mRNA vaccine that has shown promise against Uganda — Bundibugyo in mice and has pledged to send medical specialists to the Democratic Republic of the Congo>>> to assist with the outbreak.

United States — National Institutes of Health: The United States — National Institutes of Health>>>'s decision to end funding for global infectious disease research networks has drawn criticism amid ongoing outbreaks.

China: China is noted as the country where the vast majority of hantavirus cases occur annually, providing context on the global prevalence of the virus.

United States — National Institutes of Health: The United States — National Institutes of Health is a co-owner of one of the newly issued US patents, indicating its collaboration with Medicenna Therapeutics on IL-4 Superkine fusion proteins.

China: China is a country where Medicenna Therapeutics has pending patent applications, indicating its efforts to expand intellectual property protection globally.